Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98
|
作者：
Siebenhaar, Frank [1 ]
Redegeld, Frank A. [2 ]
Bischoff, Stephan C. [3 ]
Gibbs, Bernhard F. [4 ,5 ]
Maurer, Marcus [1 ]
机构：
[1] Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands
[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany
[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England
[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany
来源：
TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期
关键词：
RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;
D O I：
10.1016/j.it.2017.10.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
引用
收藏
页码：151 / 162
页数：12
相关论文
共 50 条
  • [31] Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease
    Martina, Emanuela
    Diotallevi, Federico
    Bianchelli, Tommaso
    Paolinelli, Matteo
    Offidani, Annamaria
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2021, 22 (01) : 32 - 45
  • [32] Current surgical treatments for Parkinson's disease and potential therapeutic targets
    Lee, Darrin J.
    Dallapiazza, Robert F.
    De Vloo, Philippe
    Lozano, Andres M.
    NEURAL REGENERATION RESEARCH, 2018, 13 (08) : 1342 - 1345
  • [33] Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease
    Sinha, Akshit
    Roy, Supriya
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (04) : 550 - 563
  • [34] Mast cells in atherogenesis: Actions and reactions
    Kovanen, Petri T.
    CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11 (03) : 214 - 219
  • [35] Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets
    Li, Lisha
    Lu, Jiaye
    Liu, Jun
    Wu, Junchao
    Zhang, Xinyue
    Meng, Yu
    Wu, Xiying
    Tai, Zongguang
    Zhu, Quangang
    Chen, Zhongjian
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [36] Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets
    Cai, Yongle
    Liu, Jingliu
    Wang, Bin
    Sun, Miao
    Yang, Hao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [37] Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts
    Magrone, Thea
    Magrone, Manrico
    Jirillo, Emilio
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2020, 20 (05) : 670 - 686
  • [38] Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
    Molderings, Gerhard J.
    Brettner, Stefan
    Homann, Juergen
    Afrin, Lawrence B.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [39] Update on Mast Cell Proteases as Drug Targets
    Caughey, George H.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2023, 43 (04) : 777 - 787
  • [40] Mast cell activation disease: A concise practical guide for diagnostic workup and therapeutic options
    Molderings, G. J.
    Homann, J.
    Brettner, S.
    Raithel, M.
    Frieling, T.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (30) : 1523 - 1538
12345